Brain Cancer
Researchers narrowed in on dual-treatment targets using expression and regulatory programs found in glioblastoma cells in and around the tumor.
Pathos AI Closes $62M Series C Funding Round
The financing will allow the firm to further develop its AI platform, develop drugs in best responders, and acquire new pipeline candidates.
FDA Approves Thermo Fisher Oncomine Dx Target Test as CDx for Servier's Voranigo Brain Cancer Drug
The approval expands the clinical indications for the test, which was previously approved as a CDx for non-small cell lung cancer, thyroid cancer, and bile duct cancer drugs.
Avistone Biotechnology to Launch Phase I Trial of c-MET Inhibitor in Canada
Canadian health authorities cleared the firm's application to study ANS01 as treatment for advanced solid tumor patients harboring various MET alterations.
The radiopharmaceutical, already approved for SSRT-expressing GEP-NETs, may be a new option in meningioma if future research validates findings from this small study.